Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T.

Dis Markers. 2018 Mar 12;2018:7308168. doi: 10.1155/2018/7308168. eCollection 2018. Review.

2.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

PMID:
29672836
3.

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.

Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H.

Pathol Int. 2017 Dec;67(12):597-601. doi: 10.1111/pin.12594. Epub 2017 Oct 19.

PMID:
29047227
4.

Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.

Reis H, Niedworok C, Szarvas T.

Pathology. 2017 Aug;49(5):561-562. doi: 10.1016/j.pathol.2017.04.006. Epub 2017 Jun 28. No abstract available.

PMID:
28666639
5.

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.

Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollósi P, Nyirády P, Szarvas T.

Oncotarget. 2016 Jun 28;7(26):39293-39301. doi: 10.18632/oncotarget.9828.

6.

Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer.

Nyirády P, Niedworok C, Reis H, Szarvas T.

Eur Urol. 2016 Nov;70(5):776-777. doi: 10.1016/j.eururo.2016.07.004. Epub 2016 Jul 14. No abstract available.

PMID:
27423504
7.

Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.

Szarvas T, Módos O, Niedworok C, Reis H, Szendröi A, Szász MA, Nyirády P.

Urol Oncol. 2016 Sep;34(9):388-98. doi: 10.1016/j.urolonc.2016.04.012. Epub 2016 Jun 3. Review.

PMID:
27267737
8.

Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.

Niedworok C, Panitz M, Szarvas T, Reis H, Reis AC, Szendröi A, Nyirády P, Szasz AM, Módos O, Rübben H, Vom Dorp F.

J Urol. 2016 Jun;195(6):1690-6. doi: 10.1016/j.juro.2015.11.067. Epub 2015 Dec 8.

PMID:
26678957

Supplemental Content

Loading ...
Support Center